The atypical β‐blocker S‐oxprenolol reduces cachexia and improves survival in a rat cancer cachexia model-Reference-Cited by-同舟云学术

The atypical β‐blocker S‐oxprenolol reduces cachexia and improves survival in a rat cancer cachexia model

Published:2022-11-08 Issue:1 Volume:14 Page:653-660
ISSN:2190-5991
Container-title:Journal of Cachexia, Sarcopenia and Muscle
language:en
Short-container-title:J cachexia sarcopenia muscle

Author:

Yuan Luping¹,Springer Jochen¹²^ORCID,Palus Sandra¹,Busquets Silvia³,Jové Queralt³,Alves de Lima Junior Edson³,Anker Markus S.¹²⁴,von Haehling Stephan⁵⁶,Álvarez Ladrón Natalia³,Millman Oliver³,Oosterlee Annemijn³,Szymczyk Agata³,López‐Soriano Francisco Javier³,Anker Stefan D.²⁷,Coats Andrew J.S.⁸,Argiles Josep M.³

Affiliation:

1. BIH Center for Regenerative Therapies Charité‐University Medical Center Berlin Berlin Germany

2. German Centre for Cardiovascular Research (DZHK) partner site Berlin; Charité Universitätsmedizin Berlin Berlin Germany

3. Departament de Bioquímica i Biomedicina Molecular, Cancer Research Group, Facultat de Biologia Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona Barcelona Spain

4. Department of Cardiology (CBF) Charité ‐ Universitätsmedizin Berlin Berlin Germany

5. Department of Cardiology and Pneumology University Medicine Goettingen (UMG) Goettingen Germany

6. German Center for Cardiovascular Research (DZHK), partner site Göttingen Goettingen Germany

7. Department of Cardiology (CVK) Berlin Institute of Health Center for Regenerative Therapies (BCRT) German Centre for Cardiovascular Research (DZHK) partner site Berlin; Charité Universitätsmedizin Berlin Berlin Germany

8. University of Warwick Coventry UK

Publisher

Wiley

Subject

Physiology (medical),Orthopedics and Sports Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcsm.13116

Reference39 articles.

1. Cachexia as a major public health problem: frequent, costly, and deadly

2. The metabolic basis of cancer cachexia

3. Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”

4. Definition and classification of cancer cachexia: an international consensus

5. The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer:

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined diosmin and bisoprolol attenuate cobalt chloride-induced cardiotoxicity and endothelial dysfunction through modulating miR-143-3P/MAPK/MCP-1, ERK5/CXCR4, Orai-1/STIM-1 signaling pathways;International Immunopharmacology;2024-10

2. Therapy-naïve malignancy causes cardiovascular disease: a state-of-the-art cardio-oncology perspective;American Journal of Physiology-Heart and Circulatory Physiology;2024-06-01

3. Adipose tissue rearrangement in cancer cachexia: The involvement of β3-adrenergic receptor associated pathways;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-05

4. Unraveling the lost balance: Adrenergic dysfunction in cancer cachexia;Autonomic Neuroscience;2024-02

5. Molecular Mechanisms of Cachexia: A Review;Cells;2024-01-29